19 February 2018 Novel liposomal combination treatments using dual genes knockdown in oral cancer treatment
Author Affiliations +
Proceedings Volume 10495, Biophotonics and Immune Responses XIII; 1049512 (2018) https://doi.org/10.1117/12.2291740
Event: SPIE BiOS, 2018, San Francisco, California, United States
Abstract
Small interfering RNA (siRNA) can be used to treat tumor because it can effectively knockdown target oncoprotein expression and it leads to cancer cell death and apoptosis. Hypoxia-inducible factors-1 (HIF-1) is a transcription factor gene. Its high expression of tumor hypoxia cells, activation of transcription factor HIF-1α and angiogenesis found in most cancerous tissues. HIF-1α protein in cancer cells are critical to cell survival, tumor growth and proliferation. Epidermal growth factor receptor (EGFR) gene is another common head and neck oncogene. The dual self-designed siRNA sequences were encapsulated in the lipid-calcium-phosphate (LCP) and targeted to sigma receptors on the surface of cancer cells via binding to amino ethyl anisamide (AEAA). We used human oral cancer cells to establish the xenograft animal model to study the combination therapy for therapeutic results.
© (2018) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Jyun-Sian Wu, Jyun-Sian Wu, Chia-Hsien Yeh , Chia-Hsien Yeh , Leaf Huang, Leaf Huang, Yih-Chih Hsu, Yih-Chih Hsu, } "Novel liposomal combination treatments using dual genes knockdown in oral cancer treatment", Proc. SPIE 10495, Biophotonics and Immune Responses XIII, 1049512 (19 February 2018); doi: 10.1117/12.2291740; https://doi.org/10.1117/12.2291740
PROCEEDINGS
5 PAGES


SHARE
Back to Top